Sandoz Climbs 'Pyramid' To Reach Biosimilar Success
Executive Summary
Biosimilars have turned drug development 'upside down,' where analytical confirmation outweighs clinical – a paradigm shift that must not only be embraced by the biopharmaceutical industry, but the prescribing community if US market for those products is going to be successful.
You may also be interested in...
Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Novartis AG unit Sandoz Inc. won US approval of its biosimilar Erelzi, which is referenced on Amgen's tumor necrosis factor blocker Enbrel (etanercept). The product, however, currently is caught in a patent dispute, although a recent stipulation has provided some hope for a smoother path through the legal jungle than other biosimilars may face.
Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Novartis AG unit Sandoz Inc. won US approval of its biosimilar Erelzi, which is referenced on Amgen's tumor necrosis factor blocker Enbrel (etanercept). The product, however, currently is caught in a patent dispute, although a recent stipulation has provided some hope for a smoother path through the legal jungle than other biosimilars may face.
Edging Toward Interchangeability in Biosimilars
An impressive performance by Sandoz at the July 13 Arthritis Advisory Committee on its etanercept biosimilar application suggests progress on the learning curve towards interchangeable applications.